Christof Kazda

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Sean Wharton, Thomas Blevins, Lisa Connery et al. · New England Journal of Medicine · 2023 · 378 citations

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

Christof Kazda, Ying Ding, Ronan P. Kelly et al. · Diabetes Care · 2015 · 210 citations · Full text

Treatment with <scp>LY</scp> 2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

Cristina B. Guzmán, Xiaotian Michelle Zhang, Rong Liu et al. · Diabetes Obesity and Metabolism · 2017 · 162 citations

Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study

Juan P. Frías, Stanley H. Hsia, Sarah Eyde et al. · The Lancet · 2023 · 135 citations

Diabetes Management, Medicine, Diabetes +8

Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: A randomized controlled trial in patients with type 2 diabetes beginning insulin therapy

Christof Kazda, Hiltrud Hülstrunk, Karin Helsberg et al. · Journal of Diabetes and its Complications · 2006 · 83 citations

Diabetes Management, Basal Therapy, Insulin Management +5